RUNX3, a runt-related transcription factor, has a crucial role in dorsal root ganglion neurogenesis. Recent studies have suggested that RUNX3 acts as a tumor suppressor in stomach, colon and breast cancer. However, the biological role of RUNX3 in neuroblastoma remains elusive. Here we report that high levels of RUNX3 expression contribute to the favorable outcome in patients with neuroblastoma, whereas low levels of RUNX3 expression result in poor outcome. Array-based analysis suggested that the allelic loss at chromosome 1p36 is one of the reasons why expression of RUNX3 is downregulated in advanced neuroblastomas. Interestingly, the several patients survived from neuroblastoma with both high mRNA expressions of MYCN and RUNX3, suggesting that RUNX3 high expression might overcome the aggressive behavior of MYCN. Exogenous expression of RUNX3 strongly inhibits cell proliferation and migration in neuroblastoma cell lines. Furthermore, RUNX3 reduces the stability of MYCN protein in MYCNamplified neuroblastoma cell lines, and this RUNX3-mediated MYCN degradation may depend on the physical interaction between RUNX3 and MYCN. Thus, our findings provide a tumor-suppressing mechanism by which RUNX3 inhibits the MYCN activity in neuroblastoma.
INTRODUCTION
Human neuroblastoma, a neoplasm of peripheral neural crest origin, is the most common extracranial solid tumor of childhood and accounts for 15% of cancer deaths in children. 1, 2 Despite recent advances in treatment options, aggressive neuroblastoma remains refractory to current therapy. The overall 5-year survival rate for patients with advanced-stage of neuroblastoma is 30-40%. [3] [4] [5] Neuroblastoma patients harboring genomic MYCN amplification accompanied by allelic deletion of short arm of chromosome 1 are at high risk for unfavorable outcome. Amplification of the proto-oncogene MYCN occurs in up to 25% of neuroblastoma, strongly correlating to the advanced-stage disease and the failure of chemotherapy treatment. [6] [7] [8] Loss of heterozygosity at 1p36 is found in 20-40% of neuroblastoma cases and is independently associated with progression-free survival. Thus, it has been predicted that candidates of tumorsuppressor gene may exist in this region. [9] [10] [11] RUNX3 belongs to the Runt-related gene family, whose members are pivotal regulators of neuronal development. 12, 13 RUNX3 is located at human chromosome 1p36 and its gene product acts as a tumor suppressor in various cancers [14] [15] [16] [17] [18] except neuroblastoma. A possible role of RUNX3 in neuroblastoma is suggested by its transcriptional regulation of TrkB, which was identified as an oncogene. [19] [20] [21] [22] Although the most neuroblastoma cell lines do not synthesize RUNX3 protein at detectable levels, exogenous expression of RUNX3 causes the cell death, cell cycle arrest or differentiation in neuroblastoma. 23 In this study, we quantitatively measured the expression levels of RUNX3 in 110 primary neuroblastoma samples to test the hypothesis that the inactivation of RUNX3 is independently prognostic for adverse stages of the disease. Based on clinical analyses, investigation in vitro revealed a reliable mechanism by which RUNX3 inhibits the stability and oncogenic activity of MYCN in neuroblastoma.
RESULTS
Decreased expression of RUNX3 is associated with poor prognosis in neuroblastoma patients As the RUNX3 gene is mapped to chromosome 1p36.2, which is frequently deleted in unfavorable neuroblastomas as well as other cancers, we asked whether RUNX3 could act as a tumor-suppressor gene in neuroblastoma. We then examined the expression levels of RUNX3 mRNA in 16 favorable (stage 1 or 2, single copy of MYCN and high expression of TrkA) and 16 unfavorable (stage 3 or 4, amplification of MYCN and low expression of TrkA) neuroblastoma samples by semiquantitative reverse transcription-PCR (RT-PCR). [24] [25] [26] [27] RUNX3 was expressed at higher levels in the favorable group than the unfavorable group ( Figure 1a ). This result prompted us to quantitatively measure the expression levels of RUNX3 in 110 primary samples of neuroblastomas utilizing realtime PCR. We found that RUNX3 expression levels in stage 1 and 2 patients tended to be higher (Figure 1b ). To further understand the impact of RUNX3 expression on patients outcome, we divided the clinical samples into two, such as RUNX3 high (n ¼ 22) and low (n ¼ 88) expression groups, based on the mean value of RUNX3 expression. Kaplan-Meier analysis showed that decreased expression of RUNX3 mRNA was significantly correlated with poor survival rate (P ¼ 0.016, Figure 1c ). In addition, the possible relationship between RUNX3 expression levels and various clinical and biological features from these samples were examined and summarized in Supplementary Table 1 . Significantly high levels of RUNX3 expression were found in the low-risk tumors (stages 1, 2 and 4s, Po0.001). Statistical correlation was also detectable between RUNX3 expression and the copy number of MYCN (P ¼ 0.047). The log-rank test demonstrated that several prognostic factors, including RUNX3, were significantly correlated with Figure 1 . Expression levels of RUNX3 in primary neuroblastomas. (a) Semi-quantitative RT-PCR analysis. Total RNA was prepared from primary samples with better prognosis (stages 1 and 2, MYCN single copy, n ¼ 16) and those with poor prognosis (stages 3 and 4, MYCN amplified, n ¼ 16). RT-PCR was performed to examine the expression levels of RUNX3. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is employed for loading control. (b) Quantitative real-time PCR analysis. The relative expression levels of RUNX3 in primary samples (stage 1, 2, 3, 4, and 4S) are shown. RUNX3 levels were standardized using the corresponding GAPDH value of each neuroblastoma sample. Filled triangles indicate fatal cases due to neuroblastoma cancer. (c) Kaplan-Meier survival curves of patients with neuroblastoma. Expression levels of RUNX3 in 110 primary neuroblastoma samples determined by real-time PCR were classified into two categories, such as high (open circle, n ¼ 22) and low (filled circle, n ¼ 88) expression groups, based on the mean value of RUNX3 expression levels.
clinical outcome in these 110 neuroblastoma patients (Supplementary Table 2 ). The multivariate Cox regression analysis showed that RUNX3 mRNA expression levels are not significantly associated with patient's survival only when International Neuroblastoma Staging System stages or MYCN copy number is employed (models C and E in Supplementary Table 3 ), suggesting that RUNX3 expression levels are associated with these two factors in terms of patients' survivals.
The relationship between chromosomal deletion at 1p36 and expression of RUNX3 As low expression of RUNX3 is correlated with poor patient's outcome, we sought to identify the possible mechanism underlying the suppression of RUNX3 expression. According to the data obtained from array-comparative genomic hybridization analysis using UCSF BAC array (2464 BACs, -1 Mb resolution), among 59 samples that were identified as diploid tumors, 12 tumors revealed to have a partial deletion at chromosome 1p36 (Supplementary Table 4 ), indicating that RUNX3 expression is significantly lower in the tumor cells with 1p36 loss than those without the loss. These results suggest that the gene dosage effect is one of the reasons why RUNX3 expression is decreased in aggressive neuroblastomas.
The outcome relationship between RUNX3 and MYCN expressions in neuroblastoma patients As we mentioned above, amplification of MYCN was significantly associated with low expression of RUNX3. A real-time PCR assay quantitatively measuring the expression levels of RUNX3 also supported this notion (Figure 2a) , as a majority of RUNX3 high expression cases was observed in the tumors with single copy of MYCN. Consistent with previous literatures, 28 amplified MYCN is apparently related to fatal cases indicated by filled triangles in Figure 2a . Indeed, the Kaplan-Meier survival plot clearly demonstrated that the patients with amplified copies of MYCN die more quickly than those with a single copy (Figure 2b ). These results lead us to the hypothesis that amplified copies of MYCN gene induce higher level of MYCN mRNA expression and high MYC pathway activity, resulted in death of neuroblastoma patients in which RUNX3 is expressed in a low level. To test this possibility, the expression levels of MYCN in the primary neuroblastoma samples were quantitatively measured by a real-time PCR and were compared with RUNX3 levels (Figure 2c ). Nearly all tumors in stage 4 were fatal cases (shown by filled triangles in Figure 2c ) and were associated with higher MYCN and lower RUNX3 expressions (Figure 2c , left panels). In contrast, survivals were enriched in lower International Neuroblastoma Staging System stages (1 and 2) and were generally accompanied by lower MYCN and higher RUNX3 expressions. Next, the primary neuroblastoma samples were arranged according to the expression levels of MYCN to further elucidate the correlation between MYCN and RUNX3 expressions (Figure 2c , right panels). Primary samples were classified into two groups using the mean value of MYCN as the cutoff value. We found that, among the MYCN high-expression group, patients with higher expression levels of RUNX3 tend to survive, whereas those with low expression died (Figure 2c , inset in right panels). Kaplan-Meier plot of the primary samples in which MYCN is highly expressed also supports this notion ( Figure 2d ). This result suggests that RUNX3 high expression is closely associated with survival possibility of neuroblastoma patients, even though some of them expressed high level of MYCN.
The biological function of RUNX3 in neuroblastoma cells The clinical study above promoted us to further investigate the function of RUNX3 in neuroblastoma cell lines. SK-N-BE Interaction between RUNX3 and MYCN F Yu et al (MYCN amplified) cells were transiently transfected with empty vector or increasing amounts of RUNX3 expression vector and the cell growth was examined by WST (water soluble tetrazolium salts) assay and colony formation assay. RUNX3 overexpression decreased the growth rate in a dose-dependent manner ( Figure 3a) . Similar results were obtained by conventional colony formation assay (Figure 3b ). Furthermore, colony formation assay utilizing soft agar demonstrated that overexpression of RUNX3 decreased anchorage-independent cell growth, suggesting that RUNX3 could inhibit the oncogenic property of neuroblastomaderived cell line (Figure 3c ). In order to better understand the changes in the cellular phenotype mediated by RUNX3, we tested whether RUNX3 had any role in regulating the cell migration of neuroblastoma. Toward this, Boyden chamber migration assay was performed. Overexpression of RUNX3 decreased the number of cells that migrate to the lower side of the membrane, whereas the transfection of an empty vector did not (Figure 3d ). This result indicates that RUNX3 inhibits the migration activity of neuroblastoma-derived cell line.
RUNX3 overexpression reduces MYCN expression at protein level in neuroblastoma cells As there was a close correlation between high expression of RUNX3 and favourable outcome in neuroblastoma patients in which MYCN is highly expressed, we hypothesized that RUNX3 may negatively regulate MYCN oncogenic activities, resulting in survival of neuroblastoma patients. Thus, we examined whether RUNX3 could control MYCN expression at either mRNA or protein level. Overexpression of RUNX3 decreased the MYCN proteins in a dose-and time-dependent manner (Figure 4a , left panels and Figure 4b ), whereas RT-PCR showed that the mRNA expression level of MYCN was not affected by the exogenous RUNX3 overexpression (Figure 4a, right panels) . Essentially, similar results were obtained utilizing another MYCN-amplified neuroblastoma cell line NLF. These data indicate that RUNX3 reduced the expression of MYCN at protein level rather than mRNA level, suggesting that RUNX3 negatively regulates MYCN expression by the post-translational mechanism. Immunofluorescence microscopy demonstrated that the cells in which exogenous RUNX3 (red) was overexpressed showed less degree of endogenous MYCN (green; Figure 4c degradation rate of endogenous MYCN in the absence or presence of RUNX3 was compared. Cycloheximide was used to inhibit the synthesis of new MYCN protein. Immunoblotting showed that the degradation of MYCN was accelerated by RUNX3 (Figure 4d ), suggesting a negative regulation of RUNX3 on MYCN stability. As RUNX3 is a transcription factor, degradation of MYCN may be a secondary effect of the transcriptional activation mediated by RUNX3. To exclude out this possibility, we employed RUNX3-R122C, a transcriptionally incompetent mutant of RUNX3, 29, 30 to test whether the transcriptional activity of RUNX3 is essential or not for the degradation of MYCN. Both RUNX3 wild type and RUNX3-R122C were able to facilitate the degradation of MYCN (Figure 4e) , suggesting that the transcriptional activity of RUNX3 is not necessary. Therefore, we conclude that the protein degradation of MYCN is directly mediated by RUNX3.
RUNX3 promotes ubiquitination of MYCN, resulting in MYCN degradation
The protein stability of MYCN is regulated by a complex signaling network and the degradation of MYCN is mainly promoted by an ubiquitin-proteasome pathway. [31] [32] [33] Thus, we investigated the protein stability of MYCN in the presence or absence of proteasome inhibitor MG132. Immunoblotting showed that the overexpression of RUNX3 decreased endogenous MYCN in a dosedependent manner, and this decrease was inhibited by an MG132 treatment (Figure 5a, left panel) . This result suggests that destabilization of MYCN mediated by RUNX3 depends on the proteasomal function. Similar results were obtained in another neuroblastoma cell line NLF (Figure 5a, right panel) . As the MYCN proteolysis occurs through the proteasome pathway, we asked whether ubiquitination is involved in this process. In the presence of MG132, RUNX3 efficiently facilitated the polyubiquitination of MYCN (Figure 5b, top panel) . Similarly, increasing polyubiquitination of MYCN was detected in the cell lysate immunoprecipitated by anti-MYCN antibody followed by immunoblotting with antiubiquitin antibody (Figure 5b, bottom panel) . Taken together, these results suggest that RUNX3 destabilizes MYCN through the ubiquitin-proteasome pathway.
Physical interaction between RUNX3 and MYCN As shown above, the transcriptionally deficient mutant RUNX3-R122C can also induce the degradation of MYCN as efficiently as wild-type RUNX3, suggesting that the transcriptional activity of RUNX3 is unnecessary in this process. Therefore, we speculated that RUNX3 may directly interact with MYCN to induce its degradation. To confirm this postulation, first we examined the potential interaction between exogenous RUNX3 and MYCN. HeLa cells were transiently co-transfected with expression plasmids of MYC-tagged RUNX3 (RUNX3-MYC) and HA-tagged MYCN (HA-MYCN). Anti-MYC tag antibody precipitated RUNX3-MYC and HA-MYCN. As well, anti-HA tag antibody precipitated HA-MYCN and RUNX3-MYC, confirming that RUNX3 and MYCN could interact with each other. Furthermore, the interaction between endogenous proteins was confirmed in SK-N-BE cells (Figure 6b ). As RUNX3-R122C induces the destabilization of MYCN, we also investigated whether RUNX3-R122C could bind to MYCN. We found that RUNX3-R122C co-immunoprecipitated with endogenous MYCN (Figure 6c ), suggesting that the interaction between RUNX3 and MYCN is important in the process of MYCN degradation. To identify the regions of RUNX3 required for the interaction with MYCN, in vitro translation-coupled pulldown assay was performed (Figure 6d ). Plasmids expressing a series of deletion mutants of RUNX3 protein were tranfected into HEK293 cells. Radiolabeled MYCN bound to the full length as well as several deletion constructs containing intact runt domain (deletion constructs 249, 200, D1-33 and D1-66). However, deletion constructs containing partial runt domain (D1-100, D1-133 and D1-166) failed to bind to MYCN, suggesting that the N-terminal side of the runt domain is responsible for MYCN-RUNX3 interaction. Interestingly, a deletion construct fully lacking the runt domain (D1-200) retained the interaction capability. It was assumed that transactivation domain is also capable of MYCN interaction and the C-terminal side of the runt domain interferes it. When RUNX3-MYC and HA-MYCN were co-overexpressed, we observed colocalization of these exogenous proteins in the nucleus after 24 h of transfection, further supporting our notion (Figure 6e ). Taken together, these results suggest that RUNX3 and MYCN physically interact through the runt domain of RUNX3.
RUNX3 suppresses the expression of MYCN target genes Considering the degradation of MYCN acting as a transcription factor in neuroblastoma, 31, 34 we predicted that RUNX3 may also inhibit the expression of genes targeted by MYCN. To confirm this, SK-N-BE cells were transfected with increasing amounts of RUNX3 expression plasmid. RT-PCR demonstrated that the expression levels of mRNA of MYCN-target genes, such as MDM2, ID2 and P53, [35] [36] [37] were decreased, whereas mRNA of endogenous MYCN was not affected (Figure 7a ). As well, overexpression of RUNX3 could overcome even exogenous MYCN to suppress the target (Figure 6d ). The deletion mutant 200 is the C-terminally truncated form of RUNX3 completely lacking the transactivation domain. As previous literatures demonstrated that this form of truncated RUNX3 lost tumor suppression capability, 38, 39 we assume that this deletion mutant cannot recruit additional factors required for the MYCN degradation, even though it can interact with MYCN in vitro. These results clearly demonstrated that RUNX3 inhibits transcriptional activation of MYCN-target genes, suggesting that RUNX3 can block the oncogenic signaling pathway mediated by MYCN.
DISCUSSION
In this study, we found that RUNX3 could overcome oncogenic behavior of MYCN. Consistent with our findings, RUNX3 induces the degradation of estrogen receptor a and acts as a tumor suppressor in breast cancer. 15 Thus, we conclude that RUNX3 destabilizes oncogenic proteins, such as estrogen receptor a and MYCN, to exert its tumor-suppressive function.
Threonine 50 (T50) and serine 54 (S54) are critical amino-acid residues responsible for instability of MYCN. Initial monophosphorylation at S54 by cyclin B/cdk1 stabilizes MYCN, and primes MYCN for a second phosphorylation at T50 controlled by glycogen synthase kinase 3b. MYCN protein monophosphorylated at T50 binds to E3 ligase Fbxw7 followed by ubiquitination and degradation. [31] [32] [33] 40 Early report suggested that RUNX3 transcriptionally inhibits Akt expression and therefore promotes glycogen synthase kinase 3b activation in the gastric cancer cell lines. 17 However, we did not detect the induction of glycogen synthase kinase 3b expression by RUNX3 in neuroblastoma cell line (data not shown). Rather, we showed that the transcriptionally incompetent mutant of RUNX3 could induce the degradation of MYCN, suggesting that the transcriptional activity of RUNX3 is not essential for MYCN degradation. Considering the interaction between RUNX3 and MYCN, it is possible that RUNX3 might recruit an E3 ubiquitin ligase and forms a protein complex to induce the degradation of MYCN, resulting in suppression of the transcriptional targets of MYCN. These results explain the molecular mechanism of higher survival rate observed in neuroblastoma patients in whom both MYCN and RUNX3 are highly expressed. We hypothesized that high overexpression reduced the cellular mobility as well as anchorageindependent cell growth. As these are typical indicators of the tumor-specific property of the cell lines, it was assumed that RUNX3 overexpression improves the survival rate of the patients by inhibiting the oncogenic properties of the tumor cells.
RUNX3 is located at 1p36 where nearly 30% of neuroblastoma cases had a deletion.
3-5 Consistently, we found a positive correlation between low expression of RUNX3 and the 1p36 loss. Although it has been reported that RUNX3 is inactivated by hypermethylation at its promoter region in various cancers, [12] [13] [14] we did not find statistically significant correlation between the methylation status and mRNA expression levels of RUNX3 in 110 primary neuroblastoma samples (data not shown). RUNX3 transcription factor has pivotal roles in neural development and, as far as we examined, RUNX3 expression is very low in the majority of neuroblastoma cell lines available. Therefore, we mainly employed overexpression system, rather than knockdown strategy of RUNX3. Such low level of RUNX3 could be necessary to establish the neuroblastoma cell line in which MYCN gene is amplified. We further assume that chromosomal 1p deletion is one of the major reasons responsible for the low RUNX3 expression in both primary tumors and cell lines of neuroblastoma.
Taken together, we demonstrated that RUNX3 acts as a tumorsuppressor gene in neuroblastoma. Activation of RUNX3 may suppress MYCN-mediated downstream signaling pathway. We therefore believe that the analysis of RUNX3 expression are useful for identifying low-risk neuroblastoma that are initially diagnosed as high risk and mostly increase the prognostic sensitivity.
MATERIALS AND METHODS

Clinical specimens
Tumor DNA and RNA samples were obtained from 110 tumor specimens in our Neuroblastoma Resource Bank at Chiba Cancer Center Research Institute. The specimens were kindly provided from various institutions and hospitals where informed consent was obtained. All tumors were diagnosed clinically as well as pathologically as neuroblastoma and staged according to the International Neuroblastoma Staging System criteria. MYCN copy number, TRKA mRNA expression levels and DNA index were measured as reported previously. 24 Reverse transcription-PCR and real-time PCR analyses Total RNA was prepared from the primary neuroblastoma tissues and cell lines, followed by the first strand synthesis. RT-PCR was performed according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Quantitative real-time PCR was carried out using SYBR GREEN method as the manufacturer described (Applied Biosystems, Foster City, CA, USA). Primer sequences are in the Supplementary Information.
Array-comparative genomic hybridization
Array-comparative genomic hybridization analysis was performed using UCSF BAC array (2464 BACs with 1 Mb resolution (average)) and 59 primary neuroblastomas identified as diploid were subjected to further analysis. Interaction between RUNX3 and MYCN F Yu et al Experimental procedures and the criteria for losses and gains were described previously. 24, 41 Cell culture and transfection
The human neuroblastoma cell lines (SK-N-BE, NLF) were maintained in RPMI 1640 medium (Nissui, Tokyo, Japan) supplemented with 10% heatinactivated fetal bovine serum (Invitrogen) and 100 mg/ml of penicillinstreptomycin (Invitrogen). HeLa and HEK293 cells were cultivated in Dulbecco's modified Eagle's medium supplemented with 10% heatinactivated fetal bovine serum (Invitrogen) and antibiotic mixture. Transient transfection was performed using Lipofectmine 2000 transfection reagent (Invitrogen) according to the manufacturer's instructions.
Immunoblotting, immunoprecipitation and in vitro translationcoupled pulldown assay 
Immunofluorescence analysis
For immunofluorescence, SK-N-BE and HeLa cells were grown on coverslips and transfected with indicated expression plasmids. Forty-eight hours after transfection, cells were fixed in 100% methanol for 20 min at À 20 1C, blocked in 3% bovine serum albumin, stained with the corresponding antibodies, and examined with a laser scanning confocal microscope.
Protein stability and ubiquitination assay Cells were harvested at different time points after pretreatment with cycloheximide (100 mg/ml), and the cell lysates were employed for immunoblotting. For ubiquitination assay, SK-N-BE cells were transfected with or without RUNX3. SK-N-BE cells were exposed to the proteasomal inhibitor MG132 (20 mM) for 6 h before harvest. Cell lysates were incubated with anti-MYCN or anti-ubiquitin monoclonal antibody.
Boyden chamber assay
For the Boyden chamber assay, 50 000 pre-transfected cells were resuspended in serum-free medium and plated in the top chamber of Transwell inserts (Falcon, San Jose, CA, USA). After 24 h of transfection, cells on the bottom surface of the insert were fixed in 10% formalin and stained with a crystal violet solution. Results shown are representative of three independent experiments.
Cell proliferation assay
Pre-transfected neuroblastoma cells were seeded in 96-well plates at a density of 10 3 cells per well in a final volume of 100 ml. WST assay was performed according to the manufacturer's instruction (Cell counting Kit-8; DOJINDO, Kumamoto, Japan).
Colony formation assay SK-N-BE cells were seeded at a final density of 500 000 cells/6 cm plate and allowed to attach overnight. Total amount of plasmid DNA per transfection was kept constant (2 mg) with pcDNA3. Forty-eight hours after transfection, cells were transferred to the fresh medium containing G418 (400 mg/ml). After 14 days, viable colonies were washed in phosphate-buffered saline and stained with Giemsa solution. For colony formation assay utilizing soft agar, 42 2.5 Â 10 3 cells of the RUNX3 transfected or mock transfected were seeded in triplicate in 35-mm cell culture plates containing 0.2% agar and RPMI 1640 supplemented with 10% fetal bovine serum. After 20 days, colonies with diameters 4300 mm were scored as positive.
Construction of a series of deletion mutants and a point mutant of RUNX3 RUNX3 deletion mutants were amplified by PCR. PCR primers including EcoRI and BamHI restriction sites (Supplementary Information) and the amplicons were subcloned into pcDNA3.1. The point mutated RUNX3-R122C was generated utilizing the QuikChange II XL site-directed mutagenesis kit (Agilent Technologies, Loveland, CO, USA). The PCR fragments to construct these expression plasmids were verified by DNA sequencing.
